Abstract. Glioblastoma (GB) is the most common type of malignant tumor of the central nervous system and, despite extensive research, its prognosis is poor. Although recent advances have been made in the treatment of GB with aggressive resection combined with radiochemotherapy, more than three-quarters of GB patients succumb to the disease within two years. The current study presents a highly aggressive case of small cell GB as diagnosed by histological features and immunohistochemistry for vimentin, glial fibrillary acidic protein, oligodendrocyte lineage transcription factor 2, isocitrate dehydrogenase 1-R132H and p53. The patient was treated using a multidisciplinary treatment strategy, which included temozolomide, CyberKnife radiotherapy and autologous formalin-fixed tumor vaccination. In addition, the patient developed radiation necrosis, which was treated with bevacizumab. In conclusion, three years following the initial diagnosis, the patient continues to experience a successful clinical course, and the observations of the current study demonstrate that a multidisciplinary treatment strategy may be effective for the treatment of aggressive GB.

Introduction

Despite contemporary surgery, image-guided radiotherapy and chemotherapy, glioblastoma (GB) persists or relapses in almost all patients, with tumors almost always recurring locally (1). The management of recurrent GB is variable, but approaches include the best supportive care, second surgery, reirradiation and/or systemic therapy. Promising novel therapies for GB include temozolomide (TMZ) (2), stereotactic radiotherapy [such as Gamma Knife (3) and CyberKnife (4)], immunotherapy (5) and antiangiogenic agents, including bevacizumab [a monoclonal antibody against vascular endothelial growth factor (VEGF)] (6). Emerging data suggests that the use of these therapies alone or in combination may be safe and effective (7-10).

The current study presents a case of highly aggressive GB treated with TMZ, CyberKnife radiotherapy and concurrent autologous formalin-fixed tumor vaccination (AFTV; a novel tumor vaccine consisting of autologous formalin-fixed tumor fragments) (11). Following two years without recurrence, the patient's condition deteriorated due to radiation necrosis, which subsequently lead to the initiation of a bevacizumab infusion, as previous studies have suggested that the treatment may reduce tumor necrosis (12-15). The patient's condition and magnetic resonance imaging (MRI) results markedly improved and, thus far, the patient has remained well and without recurrence. Patient provided written informed consent.

Case report

A 58-year-old female presented with left leg seizures to the local hospital. The patient had been well prior to admission. On physical examination, the patient's vital signs were normal, as were the results of the laboratory tests. Gadolinium-enhanced brain MRI revealed a mass (2-cm in diameter) around the right central sulcus (Fig. 1A). Due to a suspected high-grade glioma, the patient was transferred to the Moriyama Memorial Hospital (Tokyo, Japan) for further diagnosis and treatment. As 11C-methionine positron emission tomography (MET PET) is useful for evaluating grade, type and proliferative activity of astrocytic tumors (16), the patient underwent MET PET, which showed a ‘hot’ lesion (Fig. 1B) and lead to the suspicion of a malignant glioma. The seizures were intractable and, therefore, antiepileptic drugs were administered. In addition, a progressive left hemiparesis was observed. The tumor was highly aggressive and showed rapid growth in less than one month, as monitored by MRI (Fig. 1C).

The tumor removal by craniotomy was immediately performed under motor-evoked potential monitoring (MEP).
A parietal midline craniotomy was carried out and the right central sulcus was identified by N20 phase reversal using sensory-evoked potential. The corticotomy was performed just behind the sulcus, during which gray glioma-like tissues were removed and submitted for pathological analysis. Subtotal removal of the tumor was accomplished without any MEP abnormalities (Fig. 1D). Additional treatment with TMZ, CyberKnife radiotherapy and AFTV was also initiated following surgery, and the patient's condition remained stable without recurrence for approximately two years (Fig. 1E).

The histopathological analysis of the specimen revealed that the tumor consisted of atypical glial cells with a high nuclear to cytoplasmic ratio, proliferating in a fine fibrillary background (Fig. 2A). A stream-like arrangement of the spindled neoplastic cells, as well as a perivascular pseudorosette-like aggregation were also detected (Fig. 2B). These histological features indicated astrocytic characteristics. The neoplastic cells were also small and relatively homogeneous with only mild pleomorphism, although, the atypia of the neoplastic cells was high. The mitotic figures (5-6 mitoses/10 high-power fields), glomeruloid or epithelioid microvascular proliferation (Fig. 2C) and pseudopalisades were also detected. On the basis of these histological features, a diagnosis of small cell GB, World Health Organization (WHO) grade IV (17) and St. Anne-Mayo grade IV (18), was determined. In addition, the immunohistochemistry results were consistent with the diagnosis of GB, revealing strong immunoreactivity for vimentin (Fig. 3A) and moderate positivity for glial fibrillary acidic protein (Fig. 3B) and oligodendrocyte lineage transcription factor 2 (Fig. 3C). However, secondary GB could not be confirmed, as the immunohistochemistry results for p53 and isocitrate dehydrogenase 1 (IDH1)-R132H were negative (Fig. 3D-E) and the O6-methylguanine-DNA methyltransferase staining was weak with only <20% of positive cells (score of 1+; Fig. 3F).

The clinical and pathological observations indicated a highly aggressive case of GB and, therefore, additional therapies were required. The patient received CyberKnife radiotherapy (30 Gy in five fractions for five consecutive days) with TMZ (75 mg/m²/day for 42 consecutive days). The patient was also administered three courses of AFTV treatment, which was prepared as previously described (19), with no adverse events. The patient continued TMZ treatment at 100 mg/m²/day for five days every 28 days; however, the patient's lymphocyte count began to decline and subsequently, the TMZ treatment was discontinued.

Initially, the patient remained well without TMZ treatment; however, three months later, the patient was transferred to our hospital due to seizures and aggravation of the left hemiparesis. The MRI studies performed on admission showed an enhanced lesion caudal to the original lesion, which was considered to be a recurrence (Fig. 4A). Subsequently, the patient underwent a second cycle of CyberKnife radiotherapy, as it was considered to be the best treatment option at the time. Although the radiotherapy was administered without any adverse events, following the treatment, the patient's symptoms appeared to worsen. Eventually, the patient's condition declined to the point where the patient was unable to move unaided and, therefore, was readmitted to our hospital. Gadolinium-enhanced brain MRI on admission revealed an increase in the lesion size and fluid-attenuated inversion recovery image showed outstanding perifocal edema (Fig. 4B). This lead to the suspicion that the lesion was not due to tumor recurrence, but rather radiation necrosis. MET PET was performed and, similar to the gadolinium-enhanced brain MRI, no hot spot was detected (Fig. 4C). These results supported the diagnosis that the lesion was radiation necrosis. Several reports have suggested that bevacizumab is an effective treatment for radiation necrosis (12-15) and, therefore, the patient was enthusiastic to receive this treatment option. Bevacizumab was administered at a dose of 5 mg/kg every two weeks and, although the patient became hyperactive immediately following bevacizumab treatment, no adverse events were noted. Following three courses of bevacizumab, the MRI revealed a marked effect (Fig. 4D), which lead to the administration of three additional cycles of bevacizumab. Following meticulous rehabilitation, the patient's condition continued to improve and, finally, with family support, the patient was discharged and returned home.

Discussion

The current study presents a case of highly aggressive GB with a hot spot as visualized by MET PET, highly mitotic figures as revealed by pathological study and rapid growth as evaluated by MRI. A multidisciplinary treatment strategy was used and, three years following treatment, the patient remains well without recurrence. However, at one point, the patient's symptoms did become aggravated due to radiation necrosis, which was successfully treated using bevacizumab. The standard treatment for GB is stereotactic radiotherapy with TMZ and, in the present study, subtotal removal of the tumor was
initially performed, which was followed by the immediate initiation of CyberKnife radiotherapy with TMZ. AFTV using paraffin-embedded tissues was also administered with the predicted outcome of additional antitumor activity.

Small cell GB is a recognized subtype of GB with a highly aggressive biology, which is classified as grade IV according to the WHO grading system. These tumors generally arise in the cerebral hemispheres of adults (20,21) and do not normally appear different from ordinary GB. However, microscopy may reveal features of small cell GB morphology, including the uniform size of cells with minimal pleomorphism and monomorphic round to oval nuclei. As with ordinary GB, microvascular proliferation and pseudopalisading necrosis may also be detected. In the present study, a number of mitotic figures and apoptotic cells were also observed, supporting a high proliferative activity (20,21). The IDH1-R132H mutation is a key factor in the biology and prognosis of gliomas, and it has been shown that patients with GBs with the IDH-1-R132H
mutation exhibit improved outcomes compared with patients with wild-type IDH1 (22). It has also been shown that the IDH-1 mutation is likely to occur during the earlier stages of glioma tumorigenesis; therefore, a large proportion of low-grade gliomas possess the IDH-1 mutation. In addition, IDH1-R132H mutant-type GB may be indicative of a secondary GB progressing from low-grade glioma (23). In the present case, the immunohistochemistry results for the IDH1-R132H mutation were negative, suggesting that the primary small cell GB carried the wild-type IDH-1. The negative staining for p53 (Fig. 3D) also supported the diagnosis of primary GB; however, the differences in molecular abnormalities between small cell and ordinary GB remain undefined. The results of the current morphological analysis suggest a more aggressive phenotype for small GB than ordinary GB, but the prognostic significance of this morphological observation requires further investigation.

There has been a growing interest in therapeutic modalities based on tumor-specific immune reactions (5,19) and AFTV presents as a novel, stable and clinically durable vaccine that is simple to produce. In comparison with other novel and promising types of peptide vaccines, such as the Wilms tumor 1 protein vaccine, the use of AFTV does not require a preselection of patients according to the expression of tumor-associated antigens (19). The novel AFTV therapy was applied to the current study with the prospect of an additional antitumor effect. Although it was not possible to specifically measure the individual contribution of AFTV to the patient's response, no adverse events were attributed to this treatment and the patient continues to do well.

In the present study, the highly conformal and accurate CyberKnife radiotherapy was administered to the patient in fractions. Although numerous studies have reported the use of Gamma Knife radiotherapy for GB, this approach requires the localization and immobilization of the target with the attachment of a head frame to the skull, as well as local anesthesia and the piercing of the scalp with four screws to secure the frame to the outer table of the skull. By contrast, CyberKnife radiotherapy does not require cranial tracking, as it uses the skeletal anatomy to position the radiation beam and is as precise as frame-based approaches. Furthermore, by rendering the invasive head frames unnecessary, the CyberKnife approach facilitates fractionated treatment while maintaining radiosurgical accuracy (24).

However, reirradiation of the lesion considered to be recurrent in the current patient using the CyberKnife approach was found to only aggravate the lesion. Although, further investigation using MET PET determined the lesion to be radiation necrosis rather than tumor recurrence. Various approaches have been reported for the treatment of radiation necrosis, including corticosteroids and surgical resection. As radiation necrosis also includes damage to the vascular endothelial cells and increases in vascular permeability, the VEGF ligand has been implicated in the pathogenesis of radiation necrosis, due to its function as a vascular permeability factor. In addition, antiangiogenic therapy with bevacizumab, which binds circulating

Figure 4. Imaging studies of the patient's radiation necrosis. (A) Gadolinium-enhanced MRI showed an enhanced lesion caudal to the original lesion that appeared approximately two years following the initial surgery. (B) Gadolinium-enhanced MRI and (C) FLAIR showed growth in the size of the lesion following the second round of CyberKnife radiotherapy. (D) $^{11}$C-methionine positron emission tomography showed that the lesion and its surrounding area exhibited no hot spots, which is consistent with the diagnosis of radiation necrosis rather than tumor recurrence. Bevacizumab treatment showed a marked effect on the radiation necrosis lesion as visualized by gadolinium-enhanced (E) MRI and (F) FLAIR. MRI, magnetic resonance imaging; FLAIR, fluid attenuated inversion recovery.
VEGF, has been described as an effective treatment option for radiation injury (12-15).

At present, GB remains incurable and its median survival time following diagnosis is approximately one year. In addition, the ~3-5% of patients who survive for more than three years are classified as long-term survivors (25). In the present case, the pathological and clinical characteristics were highly aggressive upon the initial diagnosis. However, by utilizing a multidisciplinary treatment strategy, a successful clinical course has been achieved for three years following the initial diagnosis.

References

1. Kesari S: Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments. Semin Oncol 38 (Suppl 4): S2-S10, 2011
2. Friedman HS, McLendon RE, Kerby T, et al: DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16: 3851-3857, 1998.
3. Thumma SR, Elaimy AL, Daines N, et al: Long-term survival after gamma knife radiosurgery in a case of recurrent glioblastoma multiforme: a case report and review of the literature. Case Rep Med 2012: 545492, 2012.
4. Villavicencio AT, Burneikiene S, Romanelli P, et al: Survival following stereotactic radiosurgery for newly diagnosed and recurrent glioblastoma multiforme: a multicenter experience. Neurosurg Rev 32: 417-424, 2009.
5. Okada H, Kohanbash G, Zhu X, et al: Immunotherapeutic approaches for glioma. Crit Rev Immunol 29: 1-42, 2009.
6. Norden AD, Young GS, Setayesh K, et al: Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70: 779-787, 2008.
7. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
8. Park KJ, Kano H, Iyer A, et al: Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control study. J Neurooncol 107: 323-333, 2012.
9. Conti A, Pontoriero A, Arpa D, et al: Efficacy and toxicity of CyberKnife re-irradiation and ‘dose dense’ temozolomide for recurrent gliomas. Acta Neurochir (Wien) 154: 203-209, 2012.
10. Cabrera AR, Cuneo KC, Vredenburgh JJ, Sampson JH, Kirkpatrick JP: Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme. J Natl Compr Canc Netw 10: 695-699, 2012.
11. Ohno T: Autologous formalin-fixed tumor vaccine. Curr Pharm Des 11: 1181-1188, 2005.
12. Midgley R and Kerr D: Bevacizumab--current status and future directions. Ann Oncol 16: 999-1004, 2005.
13. Rahman M and Hoh BL: Avastin in the treatment for radiation necrosis: exciting results from a recent randomized trial. World Neurosurg 75: 4-5, 2011.
14. Wong ET, Huberman M, Lu XQ, Mahadevan A: Bevacizumab reverses cerebral radiation necrosis. Euro J Med Res 26: 5649-5650, 2008.
15. Furuse M, Kawabata S, Kuroiwa T and Miyatake S: Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases. J Neurooncol 102: 471-475, 2011.
16. Kato T, Shinoda J, Nakayama N, et al: Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography. AJNR Am J Neuroradiol 29: 1176-1182, 2008.
17. Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109, 2007.
18. Daumas-Dupont C, Scheithauer B, O’Fallon J and Kelly P: Grading of astrocytomas. A simple and reproducible method Cancer 62: 2152-2165, 1988.
19. Muragaki Y, Maruyama T, Iseki H, et al: Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma. Clinical article. J Neurosurg 115: 248-255, 2011.
20. Brat DJ, Parisi JE, Kleinschmidt-DeMasters BK, et al: Surgical neuropathology update: a review of changes introduced by the WHO classification of tumours of the central nervous system, 4th edition. Arch Pathol Lab Med 132: 993-1007, 2008.
21. Burger PC, Pearl DK, Aldape K, et al: Small-cell architecture—a histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol 60: 1099-1104, 2001.
22. Yan H, Parsons DW, Jin G, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773, 2009.
23. Ohgaki H and Kleihues P: Genetic profile of astrocytic and oligodendrogial gliomas. Brain Tumor Pathol 28: 177-183, 2011.
24. Oermann E, Collins BT, Erickson KT, et al: CyberKnife enhanced conventionally fractionated chemoradiation for high grade glioma in close proximity to critical structures. J Hematol Oncol 3: 22, 2010.
25. Flechl B, Acker M, Sax C, et al: Neurocognitive and sociodemographic functioning of glioblastoma long-term survivors. J Neurooncol 109: 331-339, 2012.